Skip to main content

methylnaltrexone bromide (Relistor®)

 

Status: Medicine does not meet criteria for AWMSG assessment

Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information.

Medicine details

Medicine name methylnaltrexone bromide (Relistor®)
Formulation 12 mg/0.6 ml solution for injection
Reference number 201
Indication

Treatment of opioid-induced constipation in advanced illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient

Company TMC Pharma Services Ltd
BNF chapter Gastro-intestinal system
Assessment type N/A
Status Medicine does not meet criteria for AWMSG assessment
Date of issue 13/08/2008
Follow AWTTC: